Evidence map›Paper›PMID 33565706›Full record

Trial reportDiabetes, obesity & metabolism2021

Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose-ranging study.

Bettina K Wölnerhanssen, Jürgen Drewe, Wout Verbeure, Carel W le Roux, Ludmilla Dellatorre-Teixeira, Jens F Rehfeld, Jens J Holst, Bolette Hartmann, Jan Tack, Ralph Peterli and 2 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Re-evaluation of erythritol (E 968) as a food additive.EFSA journal. European Food Safety Authority · 2023
    Article
  15. Review
  16. The sugar-free paradox: cardiometabolic consequences of erythritol.Signal transduction and targeted therapy · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Bettina K WölnerhanssenSt. Clara Research Ltd at St. Claraspital, Basel, Switzerland.
Jürgen DreweDepartment of Clinical Pharmacology and Toxicology, University Hospital of Basel, Basel, Switzerland.
Wout VerbeureTranslational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, Leuven, Belgium.
Carel W le RouxDiabetes Complications Research Centre, Conway Institute University College Dublin, Dublin, Ireland.
Ludmilla Dellatorre-TeixeiraDiabetes Complications Research Centre, Conway Institute University College Dublin, Dublin, Ireland.
Jens F RehfeldDepartment of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Jens J HolstDepartment of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Bolette HartmannDepartment of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jan TackTranslational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, Leuven, Belgium.
Ralph PeterliClarunis, Department of Surgery, St. Claraspital, Basel, Switzerland.
Christoph BeglingerSt. Clara Research Ltd at St. Claraspital, Basel, Switzerland.
Anne C Meyer-GerspachSt. Clara Research Ltd at St. Claraspital, Basel, Switzerland.ORCID 0000-0003-4104-8812
University of Basel · CHUniversity of Copenhagen · DKCatholic University of America · USUniversity College Dublin · IESt. Claraspital · CHUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine whether a dose-dependent effect in the stimulation of gut hormone release (plasma cholecystokinin [CCK], active glucagon-like peptide-1 [aGLP-1] and peptide tyrosine tyrosine [PYY]) is found for the natural sweetener erythritol. MATERIALS AND

methodsTwelve healthy, lean volunteers received solutions with 10, 25 or 50 g erythritol, or tap water enriched with

resultsWe found (a) a dose-dependent stimulation of CCK, aGLP-1 and PYY, and slowing of GE, (b) no effect on blood glucose, insulin, motilin, glucagon or glucose-dependent insulinotropic polypeptide, (c) no effect on blood lipids and uric acid, and (d) no abdominal pain, nausea or vomiting.

conclusionsSolutions with 10 and 50 g of erythritol stimulated gut hormone release. Emptying of erythritol-containing solutions from the stomach was slower compared with placebo. There was no effect on plasma glucose, insulin, glucagon, blood lipids or uric acid. All doses were well tolerated.

Indexed as

Gastric EmptyingGastrointestinal HormonesBlood GlucoseCholecystokininCross-Over StudiesDouble-Blind MethodErythritolGlucagonHumansInsulinSweetening AgentsBlood GlucoseCholecystokininErythritolGastrointestinal HormonesGlucagonInsulinSweetening Agentsappetite-related sensationsblood lipidserythritolgastric emptyinggastrointestinal symptomsgut hormonesnatural sweetenersuric acid

Identifiers

PMID33565706
PMCPMC8247993
OpenAlexW3128193856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.